The top leadership of CVS Health directed an illegal scheme to work across the corporation’s sprawling subsidiaries to drive up drug prices in the Medicare program, says a whistleblower suit that was recently unsealed in the Eastern District of Pennsylvania.
It accuses CVS of breaching firewalls between its SilverScript prescription drug plan, CVS Caremark, its pharmacy middleman, and its vast chain of retail stores. The scheme is intended to block seniors’ access to cheaper generic drugs in exchange for big rebates from the manufacturers of the drugs that were covered, the suit alleges.